Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030131 | 1.00 | SLC7A5 (0.65) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL2032146 | 1.00 | SLC7A5 (0.65) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL587006 | 1.00 | SLC7A5 (0.65) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL200720 | 1.00 | SLC7A5 (0.65) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL200721 | 1.00 | SLC7A5 (0.65) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL1253160 | 1.00 | SLC7A5 (0.65) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL15883792 | 0.84 | SLC7A5 (0.59) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL2405354 | 0.84 | SLC7A5 (0.59) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL1512910 | 0.81 | SLC7A5 (0.55) | SLC7A5USP2SLCO1B1TP53SLC1A3 | |
| SCHEMBL1512907 | 0.81 | SLC7A5 (0.55) | SLC7A5USP2SLCO1B1TP53SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0431323-A1 | Antitumor antibiotic BU-3983T | Bristol-Myers Squibb Company (US) | 1991-06-12 | — | — | EP | claimed |
| US-4421854-A | MUTANT OF ARTHROBACTER | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | claimed |
| US-4421853-A | Fermentative preparation of L-leucine | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | claimed |
| US-4329427-A | BREVIBACTERIUM CULTURE | W. R. GRACE & CO. (US) | 1982-05-11 | — | — | US | claimed |
| US-4228304-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIULCER AGENTS, BACTERICIDES, ANTITHROMBOTIC AGENTS AND FOR LIVER DISORDERS, OR AS SURFACTANTS IN DETERGENTS AND OIL ADDITIVES | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1980-10-14 | — | — | US | claimed |
| JP-3218394-A | — | — | None | — | — | JP | disclosed |
| JP-62283999-A | — | — | None | — | — | JP | disclosed |
| US-20260028375-A1 | POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES | ETH ZUERICH (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250320253-A1 | TRANSMEMBRANE PEPTIDIC ANTAGONISTS OF PLEXIN-A1 AND THEIR THERAPEUTIC USES | UNIV STRASBOURG (FR) | 2025-10-16 | — | — | US | disclosed |
| US-12410213-B2 | Polypeptides self-assembling into nanoparticles | ETH ZËRICH (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-3833676-B1 | POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES | ETH ZUERICH (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-112533938-B | Polypeptides self-assembled into nanoparticles | 苏黎世联邦理工学院 | 2025-04-25 | — | — | CN | disclosed |
| US-4421854-A | MUTANT OF ARTHROBACTER | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | disclosed |
| US-4421853-A | Fermentative preparation of L-leucine | W. R. GRACE & CO. (US) | 1983-12-20 | — | — | US | disclosed |
| US-4391907-A | GENETIC ENGINEERING | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-07-05 | — | — | US | disclosed |
| US-4329427-A | BREVIBACTERIUM CULTURE | W. R. GRACE & CO. (US) | 1982-05-11 | — | — | US | disclosed |
| EP-0030727-A2 | Method for producing L-valine by fermentation and method for producing a new microorganism of the genus Escherichia | AJINOMOTO CO., INC. (JP) | 1981-06-24 | — | — | EP | disclosed |
| US-4228304-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIULCER AGENTS, BACTERICIDES, ANTITHROMBOTIC AGENTS AND FOR LIVER DISORDERS, OR AS SURFACTANTS IN DETERGENTS AND OIL ADDITIVES | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1980-10-14 | — | — | US | disclosed |
| US-3970519-A | BREVIBACTERIUM OR CORYNEBACTERIUM | AJINOMOTO CO., INC. (JA) | 1976-07-20 | — | — | US | disclosed |
| US-3947589-A | Fungicidal methods employing amino acid derivatives | RIKAGAKU KENKYUSHO (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028375-A1 | POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES | PHAX, TPX2, MLX | SLC7A5 192/4885USP2 3111/4885SLCO1B1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.